Streptococcus pneumoniae type 9N capsular polysaccharide diphtheria CRM197 protein conjugate antigen

DB19342ApprovedInvestigationalVaccines

Streptococcus pneumoniae type 9N capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of Streptococcus pneumoniae serotype 9N individually conjugated to... The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate.

First approval: United States, 2024
Brand names: Capvaxive

Resolves to

Compound

UNIIXI7GQF2NHD

Clinical / RWD

RxNorm2686926

What you can answer from here — as of August 01, 2026

2Clinical trialsPhase, status and sponsor resolved per trial

3Structured indicationsCondition, population, route and combination as fields, not prose

1Marketed productAcross 1 country and 1 labeller

Which other approved drugs treat the same conditions as Streptococcus pneumoniae type 9N capsular polysaccharide diphtheria CRM197 protein conjugate antigen, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account